Tvardi Therapeutics, Inc. Cash Flow Conversion Efficiency
Tvardi Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has a cash flow conversion efficiency ratio of -1.101x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.23 Million) by net assets ($8.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tvardi Therapeutics, Inc. (2020–2025)
Cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2025. This chart illustrates how Tvardi Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View TVRD share price today for real-time trading data and today's change.
Tvardi Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Tvardi Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tvardi Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see TVRD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
i2S SA
PA:ALI2S
|
0.169x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
|
BSL Corp Bhd
KLSE:7221
|
-0.260x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
|
Xintela AB
ST:XINT
|
0.242x |
|
Adventa Bhd
KLSE:7191
|
-0.008x |
|
Volt Power Group Ltd
AU:VPR
|
0.043x |
|
G Capital Bhd
KLSE:7676
|
0.031x |
Annual Cash Flow Conversion Efficiency for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2025. Review TVRD FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.95 Million | $-23.50 Million | -1.122x | -108.46% |
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +793.89% |
| 2023-12-31 | $-62.06 Million | $-92.08 Million | 1.484x | +274.14% |
| 2022-12-31 | $-45.05 Million | $-17.87 Million | 0.397x | +250.16% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more